COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00080925
Recruitment Status : Completed
First Posted : April 8, 2004
Last Update Posted : March 8, 2012
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells. Eliminating the T cells from the donor cells before transplanting them and giving cyclosporine may prevent this from happening.

PURPOSE: This phase I trial is studying the side effects of T-cell-depleted allogeneic stem cell transplantation after immunoablative induction chemotherapy and reduced-intensity transplantation conditioning (chemotherapy) in treating patients with hematologic malignancies.

Condition or disease Intervention/treatment Phase
Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Biological: filgrastim Biological: graft-versus-tumor induction therapy Biological: rituximab Biological: therapeutic allogeneic lymphocytes Drug: cyclophosphamide Drug: cyclosporine Drug: cytarabine Drug: doxorubicin hydrochloride Drug: etoposide Drug: fludarabine phosphate Drug: prednisone Drug: vincristine sulfate Procedure: peripheral blood stem cell transplantation Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Primary Purpose: Treatment
Official Title: T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies
Study Start Date : February 2004
Actual Study Completion Date : December 2010

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following hematologic malignancies:

    • Acute myeloid leukemia (AML), meeting 1 of the following criteria:

      • In first complete remission (CR1), meeting 1 of the following criteria:

        • Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR), defined as 1 of the following:

          • Complex karyotype [≥ 3 abnormalities]
          • inv(3) or t(3;3)
          • t(6;9)
          • t(6;11)
          • Monosomy 7
          • Trisomy 8, alone or with an abnormality other than t(8;21), t(9;11), inv(16), or t(16;16)
          • t(11;19) (q23;p13.1)
        • Failed to achieve CR after primary induction chemotherapy
        • Secondary AML
      • In second or subsequent remission (CR2 or greater)
    • Acute lymphoblastic leukemia, meeting 1 of the following criteria:

      • In CR1, meeting 1 of the following criteria:

        • Adverse cytogenetics with minimal residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR, defined as the following:

          • Translocations involving 11q23, t(9;22), or bcr-abl rearrangement
        • Failed to achieve CR after primary induction chemotherapy
      • In CR2, if CR1 was < 12 months
      • In CR3 or greater
    • Myelodysplastic syndromes (MDS)

      • INT-2 or high-risk by International Prognostic Scoring System
      • No MDS with Fanconi anemia
    • Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

      • Accelerated phase with treatment failure after imatinib mesylate
      • Blast phase
    • Myeloproliferative disorders, meeting 1 of the following criteria:

      • Agnogenic myeloid metaplasia with adverse-risk features, meeting at least 2 of the following criteria:

        • Hemoglobin < 10 g/dL or > 10g/dL if transfusion-dependent
        • WBC < 4,000/mm^3 OR > 30,000/mm^3 OR requires cytoreductive therapy to maintain WBC < 30,000/mm^3
        • Abnormal cytogenetics, including +8, 12p-
      • Polycythemia vera or essential thrombocythemia in transformation to secondary AML
    • Myelodysplastic/myeloproliferative disease

      • Chronic myelomonocytic leukemia
    • Hodgkin's lymphoma or non-Hodgkin's lymphoma

      • Refractory lymphoma with progressive disease during combination chemotherapy
      • Relapse after OR ineligible for autologous stem cell transplantation (SCT)
    • Chronic lymphocytic leukemia

      • Treatment failure* after fludarabine, chlorambucil, and at least 1 other salvage regimen
    • Prolymphocytic leukemia (PLL), meeting 1 of the following criteria:

      • T-PLL

        • Treatment failure* after alemtuzumab and at least 1 other regimen
      • B-PLL

        • Treatment failure* after fludarabine and at least 1 other salvage regimen
    • Multiple myeloma, meeting 1 of the following criteria:

      • Relapse after autologous SCT
      • Plasma cell leukemia
      • Adverse cytogenetics, defined as 1 of the following:

        • del(13q) = 11q translocation NOTE: *Treatment failure is defined as relapse within 6 months OR failure to achieve remission
  • Less than 10% blasts in bone marrow and no circulating blasts in peripheral blood for the following diagnoses:

    • Primary or secondary leukemia
    • Refractory anemia with excess blasts
    • CML
    • Other eligible diagnosis in transformation to acute leukemia
  • Expected survival of approximately 1 year or less with conventional therapy
  • No active CNS involvement by malignancy*

    • Prior CNS involvement with no current evidence of CNS malignancy allowed NOTE: *Active CNS malignancy is defined by lymphoma: tumor mass on CT scan or leptomeningeal disease OR leukemia: blasts present on cerebrospinal fluid cytospin
  • Availability of a donor who is a sibling, parent, or offspring who shares 1 full haplotype (HLA-A, -B, or -DR)

    • Recipient and donor must have at least a 2-antigen disparity in either the host-versus-graft or graft-versus-host direction
    • Parent or offspring donor who is mismatched for a single HLA antigen (i.e., 5/6 HLA) is allowed
    • No sibling donor who is 6/6 HLA-matched OR mismatched for a single HLA antigen (i.e., 5/6 HLA)
    • No unrelated donor identified in a prior or current National Marrow Donor Program registry search



  • 18 to 55

Performance status

  • ECOG 0-2 OR
  • Karnofsky 60-100%

Life expectancy

  • At least 3 months


  • See Disease Characteristics
  • Absolute neutrophil count ≥ 1,000/mm^3*
  • Platelet count ≥ 20,0000/mm^3* (without transfusion) NOTE: *Lower values may be accepted at the discretion of the principal investigator or study chairperson if due to bone marrow involvement by malignancy


  • ALT and AST ≤ 2.5 times upper limit of normal (ULN)*
  • Bilirubin ≤ 2.5 times ULN*
  • Unconjugated hyperbilirubinemia consistent with Gilbert's syndrome allowed
  • No chronic active hepatitis B infection

    • Hepatitis B core antibody positive allowed provided patient is surface antigen negative and has no evidence of active infection
  • No hepatitis C viral infection

    • Seronegative for anti-hepatitis C antibody and detectable hepatitis C viral RNA by reverse transcriptase-polymerase chain reaction assay NOTE: *Higher levels may be accepted at the discretion of the principle investigator or study chairperson if such elevations are due to liver involvement by malignancy


  • Creatinine ≤ 1.5 mg/dL OR
  • Creatinine clearance ≥ 50 mL/min


  • LVEF ≥ 45%


  • DLCO ≥ 50% of expected value (corrected for blood hemoglobin level and alveolar volume)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 1 year after study participation
  • HIV negative
  • No active infection not responding to antimicrobial therapy
  • No psychiatric disorder that would preclude study compliance or informed consent


Biologic therapy

  • See Disease Characteristics
  • At least 2 weeks since prior monoclonal antibody therapy


  • See Disease Characteristics
  • At least 2 weeks since prior systemic chemotherapy

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified


  • Recovered from all prior therapy
  • No administration of tyrosine kinase (TK) inhibitors, including imatinib mesylate and dasatinib, during the conditioning regimen; TK inhibitor administration may resume 28 days after transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00080925

Layout table for location information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Michael R. Bishop, MD National Cancer Institute (NCI)
Layout table for additonal information Identifier: NCT00080925    
Other Study ID Numbers: 040116
First Posted: April 8, 2004    Key Record Dates
Last Update Posted: March 8, 2012
Last Verified: March 2012
Keywords provided by National Institutes of Health Clinical Center (CC):
prolymphocytic leukemia
accelerated phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
refractory chronic lymphocytic leukemia
de novo myelodysplastic syndromes
myelodysplastic/myeloproliferative neoplasm, unclassifiable
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
secondary acute myeloid leukemia
recurrent adult Hodgkin lymphoma
refractory anemia with excess blasts
refractory multiple myeloma
primary myelofibrosis
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult Burkitt lymphoma
recurrent mantle cell lymphoma
adult acute lymphoblastic leukemia in remission
adult acute myeloid leukemia in remission
chronic myelomonocytic leukemia
polycythemia vera
essential thrombocythemia
stage II multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Hematologic Neoplasms
Myelodysplastic Syndromes
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions
Neoplasms by Site